Statins and Non-Alcoholic Fatty Liver Disease Progression: Further Comments

Curr Vasc Pharmacol. 2021;19(6):673-674. doi: 10.2174/1570161119666201215141414.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors* / adverse effects
  • Liver
  • Non-alcoholic Fatty Liver Disease* / diagnosis
  • Non-alcoholic Fatty Liver Disease* / drug therapy
  • Non-alcoholic Fatty Liver Disease* / epidemiology

Substances

  • Hydroxymethylglutaryl-CoA Reductase Inhibitors